



BRIEF REPORT

Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire



ARTICLE INFO

Article history:

Received 25 January 2022

Received in revised form

31 March 2022

Accepted 1 April 2022

Available online 3 May 2022

Keywords:

Glycogen storage disease type Ib

GSD Ib

Neutropenia

SGLT2 inhibitors

SLC37A4

ABSTRACT

Purpose: This paper aims to report collective information on safety and efficacy of empagliflozin drug repurposing in individuals with glycogen storage disease type Ib (GSD Ib).

Methods: This is an international retrospective questionnaire study on the safety and efficacy of empagliflozin use for management of neutropenia/neutrophil dysfunction in patients with GSD Ib, conducted among the respective health care providers from 24 countries across the globe.

Results: Clinical data from 112 individuals with GSD Ib were evaluated, representing a total of 94 treatment years. The median age at start of empagliflozin treatment was 10.5 years (range = 0–38 years). Empagliflozin showed positive effects on all neutrophil dysfunction–related symptoms, including oral and urogenital mucosal lesions, recurrent infections, skin abscesses, inflammatory bowel disease, and anemia. Before initiating empagliflozin, most patients with GSD Ib were on G-CSF (94/112; 84%). At the time of the survey, 49 of 89 (55%) patients previously treated with G-CSF had completely stopped G-CSF, and another 15 (17%) were able to reduce the dose. The most common adverse event during empagliflozin treatment was hypoglycemia, occurring in 18% of individuals.

Conclusion: Empagliflozin has a favorable effect on neutropenia/neutrophil dysfunction–related symptoms and safety profile in individuals with GSD Ib.

© 2022 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Glucose-6-phosphate translocase (G6PT) (*SLC37A4*, OMIM 602671) shuttles glucose-6-phosphate from the cytosol to the endoplasmic reticulum where it is hydrolyzed by glucose-6-phosphatase for energy production. G6PT is expressed ubiquitously, and its deficiency causes glycogen storage disease type Ib (GSD Ib) (OMIM 232220), a rare autosomal-recessive inborn error of carbohydrate metabolism causing fasting hypoglycemia, hepatomegaly, neutropenia, and neutrophil dysfunction.^{1–5}

1,5-anhydroglucitol-6-phosphate (1,5-AG6P) is a structural analog of glucose-6-phosphate.⁶ Deficiency of G6PT results in failure to eliminate 1,5-AG6P, and its accumulation within granulocytes leads to energy deficit and subsequent apoptosis.⁶ This toxicity explains the neutrophil dysfunction and neutropenia in GSD Ib, associated with serious infections, inflammatory bowel disease (IBD), and painful mucosal lesions throughout the entire gastrointestinal tract.

The elucidation of this pathogenetic mechanism in 2019 implicated a treatment option.⁶ SGLT2 inhibitors, such as

*Correspondence and requests for materials should be addressed to Sarah C. Grünert, Department of Paediatrics, Adolescent Medicine and Neonatology, University Medical Center, Mathildenstraße 1, 79106 Freiburg, Germany. *E-mail address:* sarah.gruenert@uniklinik-freiburg.de

A full list of authors and affiliations appears at the end of the paper.

doi: <https://doi.org/10.1016/j.gim.2022.04.001>

1098-3600/© 2022 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

empagliflozin, are antidiabetic drugs that inhibit renal glucose reabsorption, thus causing glucosuria. Glucosuria decreases renal 1,5-anhydroglucitol (1,5-AG) reabsorption and thereby lowers its serum concentration.⁷ Individual treatment of 6 patients with GSD Ib with empagliflozin has shown very promising results with respect to IBD, ulcerative stomatitis, wound healing, and anemia.⁸⁻¹¹

Many scientific and regulatory hurdles need to be overcome in translating experimental studies to clinical application. After 2019 and despite the COVID-19 pandemic, off-label empagliflozin treatment in individuals with GSD Ib spread virally via both the extremely well-connected patient community and health care providers. To report collective information on safety and efficacy of empagliflozin drug repurposing in GSD Ib, we performed this questionnaire study among health care providers. Our observations reflect real-world, life-changing experiences in 112 individuals with GSD Ib and summarize the outcome, safety, and efficacy of this novel treatment.

Materials and Methods

Consent to off-label treatment with empagliflozin was obtained from the patients or parents/legal guardians by the treating health care providers. This is a retrospective data collection of anonymized data collected during regular patient care for which, in line with the Declaration of Helsinki,¹² neither individual patients' consent nor formal research ethics committee approval was required. Authors at institutions that required patient consent for the questionnaire study were responsible to obtain this permission from the patient or guardian.

After scientific presentations about the use of empagliflozin for GSD Ib at the Society for the Study of Inborn Errors of Metabolism and the International Glycogen Storage Disease 2019 conferences, in collaboration with the European Reference Network for Hereditary Metabolic Disorders, United for Metabolic Diseases, and multiple patient organizations, a Zoom webinar was organized on September 15, 2020 to share clinical and personal experiences of empagliflozin treatment in patients with GSD Ib. Meanwhile, on request, a written protocol was provided on management and monitoring (see [Supplemental Material A](#)). All participating health care providers were invited to collectively share clinical experiences by a SurveyMonkey® web-based questionnaire that was sent on July 15, 2021. Preliminary results were discussed in a Zoom meeting on September 27, 2021, and the survey was closed on October 17, 2021.

The questionnaire consisted of 29 questions exploring patient demographics, details on use of empagliflozin and G-CSF, clinical findings both before starting empagliflozin and on follow-up after starting, and adverse events (AEs) (see [Supplemental Material B](#)).

Results

Data on 112 individuals with GSD Ib from 24 different countries on 6 continents were included in this study. The median age at start of empagliflozin treatment was 10.5 years (mean [range] = 12.8 [0-38] years); 71% of the individuals were younger than 18 years. Not all data were available for all patients; data are therefore presented as x/n available.

Our data comprise information on a total of 94 treatment years. The median duration of treatment was 9.5 months (mean [range] = 10.1 [<1 -27] months). The median empagliflozin dose was 0.35 mg/kg body weight/day (median adults = 0.3 mg/kg/day, median children = 0.4 mg/kg/day, range [both groups] = 0.1-0.9 mg/kg/day). Overall, 43% of individuals (48/112) received a single dose per day, whereas in the remainder, empagliflozin was given twice daily. In 70% of individuals (78/112; individuals <18 years, 63/80 [79%] and >18 years, 15/32 [47%]), empagliflozin was started in an inpatient setting.

In most patients (78%, 85/109), the costs of empagliflozin treatment were reimbursed (mainly by health insurance, the national health system, or the hospital).

Positive effects of treatment were observed for all neutropenia-associated symptoms ([Table 1](#)). There were no major differences in outcome or AEs between pediatric and adult individuals ([Tables 1 and 2](#)) or between patients receiving 1 single dose vs 2 half doses of empagliflozin per day.

Before starting empagliflozin, 84% of the individuals (94/112) were treated with G-CSF (median [range] dose = 4.1 [0.4-15.0] $\mu\text{g}/\text{kg}/\text{day}$). Of note, in 2 patients, G-CSF was stopped in the weeks before starting empagliflozin, and these individuals were counted as having G-CSF before starting. In the G-CSF-treated patients, the most frequently reported treatment dosages/regimens were daily (52/84), 3 \times /week (12/84), 2 \times /week (10/84), every second day (5/84), and intermittent (5/84). Data on G-CSF use after the initiation of empagliflozin treatment were available for 107 patients because for 3 patients, follow-up was too short. Of these 107 individuals, 89 were on G-CSF before starting empagliflozin. Of these, 49 of 89 (55%) individuals had completely stopped G-CSF at the time of the survey, and in 15 of 89 (17%) individuals, the G-CSF dose could be significantly reduced. Information on when G-CSF treatment was discontinued is available for 46 of 49 patients: in 11 patients, G-CSF was stopped immediately; in 8 patients, within 0 to 2 weeks; in 11 patients, within 2 to 4 weeks; in 5 patients, within 5 to 8 weeks; in 3 patients, within 9 to 12 weeks; in 2 patients each, within 4 and 5 months; and in 1 patient each, after 6, 7, 8, and 15 months.

An AE is defined as any unfavorable and unintended event that is observed after administration of a pharmaceutical product. In 77 patients (69%), no AEs were reported; for 23 patients, 1 AE was reported (20.5%); for 6 patients (5%), 2 AEs were reported; and for 3 patients (3%), 3 AEs were reported ([Table 2](#)).

Table 1 Clinical findings before and during use of empagliflozin

Clinical/Laboratory Findings	Before Empagliflozin			During Empagliflozin		
	All	Individuals <18 y	Individuals >18 y	All	Individuals <18 y	Individuals >18 y
Neutropenia						
Severe (ANC <500/ μ L)	29% (32/112)	30% (24/80)	25% (8/32)	10% (11/108)	12% (9/76)	6% (2/32)
Moderate (ANC 500-1000/ μ L)	41% (46/112)	41% (33/80)	40% (13/32)	22% (24/108)	20% (15/76)	28% (9/32)
Mild (ANC 1000-1500/ μ L)	13% (15/112)	14% (11/80)	13% (4/32)	15% (16/108)	15% (11/76)	16% (5/32)
No	17% (19/112)	15% (12/80)	22% (7/32)	53% (57/108)	54% (41/76)	50% (16/32)
Recurrent oral/anogenital mucosal lesions	68% (76/112)	69% (55/80)	66% (21/32)	13% (14/109) ^a	17% (13/78)	3% (1/31)
Recurrent bacterial/skin infections	54% (61/112)	50% (40/80)	66% (21/32)	8% (9/109) ^a	9% (7/78)	6% (2/31)
IBD						
Severe	10% (11/110)	10% (8/78)	9% (3/32)	0% (0/106)	0% (0/76)	0% (0/30)
Moderate	27% (30/110)	26% (20/78)	31% (10/32)	6% (6/106)	5% (4/76)	7% (2/30)
Mild	23% (25/110)	24% (19/78)	19% (6/32)	16% (17/106)	17% (13/76)	13% (4/30)
No	40% (44/110)	40% (31/78)	40% (13/32)	78% (83/106)	77% (59/76)	80% (24/30)
Anemia						
Requiring red blood cell transfusions	4% (5/112)	5% (4/80)	3% (1/32)	0% (0/110)	0% (0/78)	0% (0/32)
Requiring iron therapy	37% (41/112)	35% (28/80)	40% (13/32)	16% (18/110)	15% (12/78)	19% (6/32)
Requiring no intervention	32% (36/112)	31% (25/80)	72% (23/32)	14% (15/110)	18% (14/78)	3% (1/32)
No	27% (30/112)	29% (23/80)	22% (7/32)	70% (77/110)	67% (52/78)	78% (25/32)
G-CSF treatment	84% (94/112)	80% (64/80)	88% (28/32)	37% (40/107)	42% (32/75)	25% (8/32)
Median dose, μ g/kg/day	4.0	—	—	1.7	—	—
Daily dose	52/110	—	—	—	—	—
3 \times /week	12/110	—	—	—	—	—
2 \times /week	10/110	—	—	—	—	—
Every second day	5/110	—	—	—	—	—
Intermittent	5/110	—	—	—	—	—

ANC, absolute neutrophil count; IBD, inflammatory bowel disease.

^aMilder, rarer, and less painful than before.

The most common AE was level 3 hypoglycemia, defined as <3.0 mmol/L (54 mg/dL) and characterized by altered mental and/or physical status requiring assistance. This occurred in 18% (20/111) of all patients; of these 20 patients, 13 of 77 (17%) started in an inpatient setting and 7 of 34 (21%) started in an outpatient setting. The dosing frequency had no impact on the frequency and risk of hypoglycemia (21% [10/48] of patients receiving a single dose of empagliflozin per day, 17% [11/64] of patients receiving empagliflozin twice daily). Hypoglycemia occurred in both pediatric ($n = 16$) and adult ($n = 4$) patients (median age of patients with hypoglycemia = 6 years, range = 0-26 years). Nine patients (8%, 8 children, 1 adult; median age = 6 years) required inpatient treatment, whereas 11 (8 children, 3 adults, median age = 8 years) required outpatient treatment for this AE.

The most severe AE was lactic acidosis, reported in 6 patients (5 children, 1 adult), of whom 5 required hospitalization (4 children, 1 adult). One of the adult individuals also had significant ketoacidosis. In 1 adult patient, 2 decompensations requiring intensive care unit observation were reported, both associated with gastroenteritis and dehydration (1 caused by norovirus, 1 unknown).

Discussion

The SGLT2 inhibitor empagliflozin is approved for adults with type 2 diabetes mellitus, the most prevalent acquired disorder of carbohydrate metabolism. GSD Ib is an ultra-rare, inherited disorder (the overall prevalence is about 1 in 1,000,000), and experimental work underlying empagliflozin treatment in GSD Ib was only very recently published.⁶ The first case studies in 2020 reported successful use of empagliflozin to treat neutropenia and neutrophil dysfunction-related symptoms and signs in individuals with GSD Ib. Subsequently, the treatment gained much interest within the metabolic community and patient support groups, which now enables us to present data on 112 patients with GSD Ib treated with empagliflozin.

We demonstrate that empagliflozin leads to improvement of neutropenia and shows positive effects on all neutropenia and neutrophil dysfunction-related symptoms, including oral and urogenital mucosal lesions, recurrent infections, skin abscesses, IBD, and anemia. Whereas before start of empagliflozin treatment, 70% of patients either had severe or moderate neutropenia despite G-CSF treatment, 53% of patients achieved normal neutrophil counts on empagliflozin

Table 2 Adverse events during empagliflozin use

	Level 3 Hypoglycemia	Allergic/ Anaphylactic Reaction	Fungal Oral Infections	Fungal Genital Infections	Urinary Tract Infection	Skin Rash	Pruritus	Ketoacidosis	Lactic Acidosis	Dehydration
AE not reported, <i>n</i> (%)	91 (82)	111 (99)	112 (100)	109 (97)	104 (93)	109 (97)	111 (99)	111 (99)	106 (95)	111 (99)
AE occurred, <i>n</i> (%)	20 (18)	1 (1)	—	3 (3)	8 (7)	3 (3)	1 (1)	1 (1)	6 (5)	1 (1)
AE occurred in individuals <18 y, <i>n</i> (%)	14 (18)	1 (1)	—	1 (1)	5 (6)	2 (3)	1 (1)	—	3 (4)	—
AE occurred in individuals >18 y, <i>n</i> (%)	6 (14)	0	0	2 (5)	3 (7)	1 (2)	0	1 (2)	3 (7)	1 (2)
AE requiring hospitalization, <i>n</i> (%)	9 (8.1)	—	—	—	—	—	—	1 (0.9)	5 (4.5)	1 (0.9)
AE requiring outpatient treatment, <i>n</i> (%)	11 (10)	1 (1)	—	3 (3)	6 (5)	3 (3)	1 (1)	—	1 (1)	—
Median age of affected patients (y)	6	37	NA	6	5	12	17	23 ^a	5	23 ^a
Median age of patients requiring hospitalization (y)	6	NA	NA	NA	2	NA	NA	23 ^a	6	23 ^a
Median age of patients requiring outpatient treatment (y)	8	37	NA	5.8	7	12	17	NA	6	NA
Occurrence of AE per 10 treatment years	2.1	0.1	—	0.3	0.8	0.3	0.1	0.1	0.6	0.1
Treatment duration (y) until first AE occurrence	4.7	94.3	—	31.4	11.8	31.4	94.3	94.3	15.7	94.3
Prevalence	Very common	Common	NA	Common	Common	Common	Common	Common	Common	Common

Very common: >1 in 10 (0.1 = 10%), common: 1-10 in 100 (0.01-0.1 = 1%-10%), uncommon: 1-10 in 1000, rare: 1-10 in 10,000, very rare: <1 in 10,000.

AE, adverse event; NA, not applicable.

^aTwo episodes occurred in the same patient.

treatment. At the time of data collection, 49 of 89 previously G-CSF-treated patients had stopped G-CSF after the initiation of empagliflozin; of these, 30 (61%) had stopped within the first month. It is conceivable that even more patients could stop G-CSF treatment. Potential reasons why this has not been done yet are (1) short duration of treatment/follow-up at time of data collection, (2) limited experience with empagliflozin for this indication, and (3) hesitation to stop G-CSF in case of clinical improvement but persistent (mild) neutropenia.

The efficacy of empagliflozin was similar in both pediatric and adult patients. In patients with type 2 diabetes mellitus, empagliflozin is administered once daily. Because of the risk of hypoglycemia, 57% of the patients with GSD Ib in our study received 2 half doses of empagliflozin per day. The dosing frequency appeared not to have a significant impact on efficacy. Plasma 1,5-AG concentrations have not been systematically analyzed in this patient cohort. Therefore, it is yet unknown which dosing regimen is superior in lowering the plasma concentration of this toxic metabolite.

Empagliflozin has a good safety profile in individuals with GSD Ib. Although most of the reported AEs were common, as defined by occurrence in 1 to 10 per 100 patients treated (1%-10%), mostly these were nonserious AEs and manageable in an outpatient setting. The most frequently reported AE was hypoglycemia (occurred in 18% of subjects). Hypoglycemia is a common finding in patients with GSD Ib, so it is impossible to determine from these data whether empagliflozin treatment contributed to these episodes. The same is true for lactic acidosis. Hypoglycemia was not more frequent in patients who received empagliflozin in 1 single dose per day than those who received divided dosing. Because empagliflozin is not approved for use in children, we were especially alert for AEs in younger children. We observed that the AE hypoglycemia was reported with equal frequency in both in individuals <18 years (18%) and >18 years (14%); for all other AEs, the size of the cohort is too small to draw firm conclusions. Therefore, we advise to consider initiation of empagliflozin treatment in an inpatient setting in preverbal children or in patients with GSD Ib with unstable glucose control.

Based on the observed serious AE of ketoacidosis, requiring intensive care unit treatment twice in a 23-year-old patient during gastroenteritis with dehydration, we would like to emphasize that sufficient fluid intake should generally be guaranteed. In case of fever, decreased gastrointestinal intake, acute vomiting, and/or diarrhea, the role of empagliflozin in the development of acute metabolic decompensation (eg, hypoglycemia \pm lactic acidosis) and dehydration (caused by ongoing glucosuria) should be carefully balanced against risks and consequences of short-term empagliflozin discontinuation on neutropenia and neutrophil dysfunction. Effects of SGLT2 inhibition on both glucosuria and neutropenia/neutrophil dysfunction may pharmacodynamically differ. It has been observed that blood concentrations of 1,5-AG6P and 1,5-AG only decrease to a new steady state approximately 15 to 30 days

after initiation of empagliflozin in patients with GSD Ib.⁸ Although for decades the neutrophil lifespan has been considered a matter of hours,¹³ this idea has recently been challenged, estimating a lifespan of 5.4 days.¹⁴ Therefore, it may be safer to stop empagliflozin during intercurrent illness for 1 to 2 days in patients with GSD Ib until glucose and fluid homeostasis are secured.

This report of the clinical experience of 112 pediatric and adult individuals with GSD Ib clearly shows how SGLT2 inhibitors, among the most widely prescribed drugs for a very common acquired disease, can be repurposed to improve medical outcomes for individuals with an ultra-rare inherited disease. Several methodological limitations concerning this study should be considered. This study is retrospective, and standardized clinical and biochemical outcome parameters have not yet been defined, which made a more detailed study difficult. In addition, despite the best efforts, the authors will not have been able to include all patients with GSD Ib treated with empagliflozin to date. For individual patients with GSD Ib, these positive results should be carefully weighed against the reported AEs and the known disadvantages and complications, especially of long-term use of G-CSF, such as the risk of malignancies. Preliminary evidence suggests that empagliflozin has the potential to become the first-line treatment for neutropenia and neutrophil dysfunction-related symptoms in individuals with GSD Ib. Future studies are warranted on the origin of 1,5-AG, long-term safety and efficacy profile of empagliflozin, pharmacokinetics/-genetics, and patient-reported outcomes in different age groups.

Data Availability

Data are available on request.

Acknowledgments

Several authors of this publication are members of the European Reference Network for Rare Hereditary Metabolic Disorders (Project ID No. 739543). We are grateful to Hanka Dekker and Caroline van Essen (representing Volwassen Kinderen en Stofwisselingsziekten, the Dutch metabolic patient organization) and Enrique Contreras (representing Asociación Española de Enfermos de Glucogenosis, the Spanish glycogen storage disease patient organization) for co-creation of the webinars and their input during the development of the questionnaire. This research has been supported by Nina Contreras D'Agosto, a little girl living with Glycogen Storage Disease type 1b, and her parents Marta D'Agosto and Enrique Landelino Contreras "Lande", through the platform "Nina The Warrior" and its thousands of followers and donors at www.ninalaguerrera.org. They are members of the Board of Directors of the Global GSD1b Research Alliance

“CureGSD1b” (www.curegsd1b.org), a growing worldwide community with nearly 200 GSD1b patients and families.

Author Information

Conceptualization: S.C.G., T.G.J.D., S.B.W.; Data Curation: all authors; Formal Analysis: S.C.G., T.G.J.D., S.B.W.; Methodology: S.C.G., T.G.J.D., S.B.W.; Project Administration: S.C.G., T.G.J.D., S.B.W.; Software: T.G.J.D.; Supervision: S.C.G., T.G.J.D., S.B.W.; Writing-original draft: S.C.G., T.G.J.D., S.B.W.; Writing-review and editing: S.C.G., T.G.J.D., K.A., K.A.T., D.B., J.B., A.B., M.B., D.B., M.B.K., A.B., A.C., W.C., A.C., C.D., H.D., M.D.M., H.E., Y.F., C.F.D.S., M^a.C.G.J., S.G., D.H., J.H., R.H., L.H.F., A.H.B., L.M.H., M.H., S.K.U., B.K., S.K., G.K., M.L., N.L., K.M., A.M.K.K., E.M.M., A.M., S.E.M., J.J.M., H.M., H.M., C.O., K.P., P.Q.F., D.R., A.R., R.S., H.C.S., P.S., J.S., R.S., K.M.S., G.T., M.Z.T., A.D.T., M.T., S.T., S.A.S.V., E.V., N.W., P.Z., S.B.W.

Ethics Declaration

This is a retrospective collection of anonymized data collected during regular patient care, for which, in line with the Declaration of Helsinki,¹² neither individual patients' consent nor formal research ethics committee approval was required. Authors at institutions that required patient consent were responsible to obtain this permission from the patient or guardian.


Conflict of Interest

All authors declare no conflicts of interest.

Additional Information

The online version of this article (<https://doi.org/10.1016/j.gim.2022.04.001>) contains supplementary material, which is available to authorized users.

Authors

Sarah C. Grünert^{1,*} , Terry G.J. Derks², Katarina Adrian³, Khalid Al-Thihli⁴, Diana Ballhausen⁵, Joanna Bidiuk⁶, Andrea Bordugo⁷, Monica Boyer⁸, Drago Bratkovic⁹, Michaela Brunner-Krainz¹⁰, Alberto Burlina¹¹, Anupam Chakrapani¹², Willemijn Corpeleijn¹³, Alison Cozens¹⁴, Charlotte Dawson¹⁵, Helena Dhamko¹⁶, Maja Djordjevic Milosevic¹⁷, Hernan Eiroa¹⁸,

Yael Finezilber¹⁹, Carolina Fischinger Moura de Souza²⁰, Maria Concepción García-Jiménez²¹, Serena Gasperini²², Dorothea Haas²³, Johannes Häberle²⁴, Rebecca Halligan²⁵, Law Hiu Fung²⁶, Alexandra Hörbe-Blindt²⁷, Laura Maria Horka²⁸, Martina Huemer^{24,29}, Sema Kalkan Uçar³⁰, Bozica Kecman¹⁷, Sebile Kilavuz³¹, Gergely Kriván³², Martin Lindner³³, Natalia Lüsebrink³³, Konstantinos Makrilakis³⁴, Anne Mei-Kwun Kwok³⁵, Esther M. Maier³⁶, Arianna Maiorana³⁷, Shawn E. McCandless^{38,39}, John James Mitchell⁴⁰, Hiroshi Mizumoto⁴¹, Helen Mundy⁴², Carlos Ochoa⁴³, Kathryn Pierce⁴⁴, Pilar Quijada Fraile⁴⁵, Debra Regier⁴⁶, Alessandro Rossi⁴⁷, René Santer⁴⁸, Hester C. Schuman⁴⁹, Piotr Sobieraj⁶, Johannes Spenger⁵⁰, Ronen Spiegel⁵¹, Karolina M. Stepień⁵², Galit Tal⁵³, Mojca Zerjav Tanšek⁵⁴, Ana Drole Torkar⁵⁴, Michel Tchan^{55,56}, Santhosh Thyagu¹⁶, Samantha A. Schrier Vergano⁵⁷, Erika Vucko⁵⁸, Natalie Weinhold⁵⁹, Petra Zsidedg⁶⁰, Saskia B. Wortmann^{50,61}

Affiliations

¹Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Centre-University of Freiburg, Faculty of Medicine, Freiburg, Germany; ²Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center of Groningen, University of Groningen, Groningen, The Netherlands; ³Department of Pediatrics, Queen Silvias Childrens Hospital, Sahlgrenska University Hospital, Göteborg, Sweden; ⁴Genetic and Developmental Medicine Clinic, Sultan Qaboos University Hospital, Muscat, Oman; ⁵Pediatric Metabolic Unit, Pediatrics, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; ⁶Department of Internal Medicine, Hypertension and Vascular Diseases, Medical University of Warsaw, Warsaw, Poland; ⁷Inherited Metabolic Disease Unit, Pediatric Clinic C, Woman and Child Department, Azienda Ospedaliera Università Integrata, Verona, Italy; ⁸Division of Metabolic Disorders, CHOC Children's Hospital, Orange, CA; ⁹Metabolic Clinic, Women's and Children's Hospital, North Adelaide, South Australia, Australia; ¹⁰University Children's Hospital Graz, Graz, Austria; ¹¹Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, Padua, Italy; ¹²Department of Metabolic Medicine, Great Ormond Street Hospital, London, United Kingdom; ¹³Department of Pediatrics, Division of Metabolic Disorders, Emma Children's Hospital, Gastroenterology, Endocrinology & Metabolism, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ¹⁴Royal Hospital for Children and Young People, Edinburgh, United Kingdom; ¹⁵Department of Endocrinology, Diabetes and Metabolism, University Hospitals Birmingham, Birmingham, United Kingdom; ¹⁶Division of Medical Oncology and

Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; ¹⁷Metabolic and Genetic Department, Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Belgrade, Serbia; ¹⁸Servicio de Errores Congenitos del Metabolismo, Hospital de Pediatría “J.P. Garrahan”, Buenos Aires, Argentina; ¹⁹Metabolic Diseases Unit and Internal Medicine Department A, Sheba Medical Center, Ramat Gan, Israel; ²⁰Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; ²¹Neurometabolic Unit, Pediatric Department, Miguel Servet University Hospital, Zaragoza, Spain; ²²Metabolic Rare Diseases Unit, Paediatric Department, San Gerardo Hospital, Monza, Italy; ²³Center for Child and Adolescent Medicine, Division of Child Neurology and Metabolic Medicine, University Hospital Heidelberg, Heidelberg, Germany; ²⁴Division of Metabolism and Children’s Research Center, University Children’s Hospital Zurich, Zürich, Switzerland; ²⁵Department of Metabolic Medicine, The Royal Children’s Hospital, Melbourne, Victoria, Australia; ²⁶Department of Pediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong Island, Hong Kong; ²⁷Eltern-Kind-Zentrum Prof. Hess, Medical Centre Bremen Mitte, Bremen, Germany; ²⁸Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland; ²⁹Department of Pediatrics, University Children’s Hospital Basel and University of Basel, Basel, Switzerland; ³⁰Division of Metabolism and Nutrition, Department of Pediatrics, Ege University Children’s Hospital, Izmir, Turkey; ³¹Division of Pediatric Metabolism, Department of Pediatrics, University of Health Sciences, Van Training and Research Hospital, Van, Turkey; ³²Department for Pediatric Hematology and Hemopoietic Stem Cell Transplantation, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary; ³³Department of Pediatric Neurology, University Children’s Hospital Frankfurt, Frankfurt, Germany; ³⁴First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece; ³⁵Department of Pediatrics and Adolescent Medicine, Hong Kong Children’s Hospital, Hong Kong; ³⁶Section of Inborn Errors of Metabolism, Dr. von Hauner Children’s Hospital, University of Munich, Munich, Germany; ³⁷Division of Metabolism, Department of Pediatric Subspecialties, Ospedale Pediatrico Bambino Gesù, Istituti di Ricovero e Cura a Carattere Scientifico, Rome, Italy; ³⁸Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO; ³⁹Department of Genetics and Metabolism, Children’s Hospital Colorado, Aurora, CO; ⁴⁰Division of Pediatric Endocrinology, McGill University Health Center, Montreal, Quebec, Canada; ⁴¹Department of Pediatrics, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan; ⁴²Evelina Children’s Hospital, London, United Kingdom; ⁴³Department of Pediatrics, Complejo Asistencial de Zamora, Zamora, Spain; ⁴⁴York University, Toronto, Ontario, Canada; ⁴⁵Reference Center for Inherited Metabolic Disorders, Department of Pediatrics,

Hospital Universitario 12 de Octubre, Madrid, Spain; ⁴⁶Genetics and Metabolism, Children’s National Hospital, Washington DC; ⁴⁷Section of Paediatrics, Department of Translational Medicine, University of Naples “Federico II”, Naples, Italy; ⁴⁸Department of Pediatrics, University Medical Center Eppendorf, Hamburg, Germany; ⁴⁹Mediclinic Kloof Hospital, Pretoria, South Africa; ⁵⁰University Children’s Hospital Salzburg, Salzburg, Austria; ⁵¹Pediatric Department B, Emek Medical Center, Afula, Rappaport School of Medicine, Technion, Haifa, Israel; ⁵²Adult Inherited Metabolic Diseases, Salford Royal NHS Foundation Trust, Salford, United Kingdom; ⁵³Metabolic Clinic, Ruth Rappaport Children’s Hospital, Rambam Health Care Campus, Haifa, Israel; ⁵⁴University Children’s Hospital, Department of Endocrinology, Diabetes and Metabolism, Ljubljana University Medical Centre, Ljubljana, Slovenia; ⁵⁵Department of Genetic Medicine, Westmead Hospital, Sydney, New South Wales, Australia; ⁵⁶Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; ⁵⁷Division of Medical Genetics and Metabolism, Children’s Hospital of The King’s Daughters, Norfolk, VA; ⁵⁸Division of Genetics, Birth Defects, and Metabolism, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL; ⁵⁹Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Center of Chronically Sick Children, Berlin, Germany; ⁶⁰Newborn Screening and Metabolic Centre, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary; ⁶¹Amalia Children’s Hospital, Nijmegen, The Netherlands

References

- Bali DS, El-Gharbawy A, Austin S, Pendyal S, Kishnani PS. Glycogen storage disease type I. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., eds. *GeneReviews® [Internet]*. Seattle, Washington: University of Washington; 2006.
- Gerin I, Veiga-da-Cunha M, Achouri Y, Collet JF, Van Schaftingen E. Sequence of a putative glucose 6-phosphate translocase, mutated in glycogen storage disease type Ib. *FEBS Lett.* 1997;419(2-3):235–238. [http://doi.org/10.1016/s0014-5793\(97\)01463-4](http://doi.org/10.1016/s0014-5793(97)01463-4).
- Dale DC, Bolyard AA, Marrero T, et al. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. *Curr Opin Hematol.* 2019;26(1):16–21. <http://doi.org/10.1097/MOH.0000000000000474>.
- Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. *J Pediatr.* 2000;137(2):187–191. <http://doi.org/10.1067/mpd.2000.105232>.
- Chen MA, Weinstein DA. Glycogen storage diseases: diagnosis, treatment and outcome. *Transl Sci Rare Dis.* 2016;1(1):45–72.
- Veiga-da-Cunha M, Chevalier N, Stephenne X, et al. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. *Proc Natl Acad Sci U S A.* 2019;116(4):1241–1250. <http://doi.org/10.1073/pnas.1816143116>.
- Fortuna D, McCloskey LJ, Stickley DF. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to

- alter plasma 1,5-anhydroglucitol. *Clin Chim Acta*. 2016;452:138–141. <http://doi.org/10.1016/j.cca.2015.11.010>.
8. Wortmann SB, Van Hove JLK, Derks TGJ, et al. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. *Blood*. 2020;136(9):1033–1043. <http://doi.org/10.1182/blood.2019004465>.
 9. Grünert SC, Elling R, Maag B, et al. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib. *Orphanet J Rare Dis*. 2020;15(1):218. <http://doi.org/10.1186/s13023-020-01503-8>.
 10. Mikami M, Arai A, Mizumoto H. Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib. *Pediatr Int*. 2021;63(11):1394–1396. <http://doi.org/10.1111/ped.14629>.
 11. Rossi A, Miele E, Fecarotta S, et al. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report. *Ital J Pediatr*. 2021;47(1):149. <http://doi.org/10.1186/s13052-021-01100-w>.
 12. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191–2194. <http://doi.org/10.1001/jama.2013.281053>.
 13. Cartwright GE, Athens JW, Wintrobe MM. The kinetics of granulopoiesis in normal man. *Blood*. 1964;24:780–803.
 14. Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. *Blood*. 2016;127(18):2173–2181. <http://doi.org/10.1182/blood-2016-01-688887>.